This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vigil, A. Articles by García-Sastre, A. Search for Related Content PubMed PubMed Citation Articles by Vigil, A. Articles by García-Sastre, A.

Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus

Departments of ¹ Microbiology, ² Gene and Cell Medicine, ³ Medicine, Division of Infectious Diseases, and ⁴ Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, New York

Requests for reprints: Adolfo García-Sastre, Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029. Phone: 212-241-7769; Fax: 212-534-1684; E-mail: adolfo.garcia-sastre{at}mssm.edu.

Naturally occurring strains of Newcastle disease virus (NDV) have shown oncolytic therapeutic efficacy in preclinical studies and are currently in clinical trials. Here, we have evaluated the possibility to enhance the cancer therapeutic potential of NDV by means of reverse genetics. Mice bearing s.c. implanted CT26 tumors were treated with intratumoral (i.t.) injections of a recombinant NDV modified to contain a highly fusogenic F protein. These treated mice exhibited significant reduction in tumor development compared with mice treated with the unmodified virus. Furthermore, mice in a CT26 metastatic tumor model treated with an i.v. injection of the genetically engineered NDV exhibited prolonged survival compared with wild-type control virus. In addition, we examined whether the oncolytic properties of NDV could be improved by expression of immunostimulatory molecules. In this regard, we engineered several NDVs to express granulocyte macrophage colony-stimulating factor, IFN-, interleukin 2 (IL-2), or tumor necrosis factor , and evaluated their therapeutic potential in an immunocompetent colon carcinoma tumor model. Mice bearing s.c. CT26 tumors treated with i.t. injections of recombinant NDV expressing IL-2 showed dramatic reductions in tumor growth, with a majority of the mice undergoing complete and long-lasting remission. Our data show the use of reverse genetics to develop enhanced recombinant NDV vectors as effective therapeutic agents for cancer treatment. [Cancer Res 2007;67(17):8285–92]

This article has been cited by other articles:

				E. Carnero, W. Li, A. V. Borderia, B. Moltedo, T. Moran, and A. Garcia-Sastre Optimization of Human Immunodeficiency Virus Gag Expression by Newcastle Disease Virus Vectors for the Induction of Potent Immune Responses J. Virol., January 15, 2009; 83(2): 584 - 597. [Abstract] [Full Text] [PDF]

				P. J. Mahon, A. M. Mirza, T. A. Musich, and R. M. Iorio Engineered Intermonomeric Disulfide Bonds in the Globular Domain of Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein: Implications for the Mechanism of Fusion Promotion J. Virol., November 1, 2008; 82(21): 10386 - 10396. [Abstract] [Full Text] [PDF]

				M. D. Gainey, M. J. Manuse, and G. D. Parks A Hyperfusogenic F Protein Enhances the Oncolytic Potency of a Paramyxovirus Simian Virus 5 P/V Mutant without Compromising Sensitivity to Type I Interferon J. Virol., October 1, 2008; 82(19): 9369 - 9380. [Abstract] [Full Text] [PDF]

				Q. Gao, M.-S. Park, and P. Palese Expression of Transgenes from Newcastle Disease Virus with a Segmented Genome J. Virol., March 15, 2008; 82(6): 2692 - 2698. [Abstract] [Full Text] [PDF]